isocarboxazid

Trade name: marplan

Small moleculeapproved

Approved

Jul 1, 1959

Isocarboxazid (Marplan, Marplon, Enerzer) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class used as an antidepressant. In vivo and in vitro studies demonstrated inhibition of MAO in the brain, heart, and liver. Depression is a complicated disease that is not fully understood. It is thought that depression may be linked to an imbalance of chemicals within the brain. When depression occurs, there may be a decrease in the amount of chemicals released from nerve cells in the brain. These chemicals are called monoamines. Monoamines are broken down by a chemical called monoamine oxidase. Isocarboxazid prevents monoamine oxidase from breaking down the monoamines. This results in an increased amount of active monoamines in the brain. By increasing the amount of monoamines in the brain, the imbalance of chemicals thought to be caused by depression is altered. This helps relieve the symptoms of depression. Isocarboxazid works by irreversibly blocking the action of a chemical substance known as monoamine oxidase (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase–A (MAO-A) and monoamine oxidase–B (MAO-B). The reduced MAO activity results in an increased concentration of these neurotransmitters in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. This increased availability of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors. May be used to treat major depressive disorder. — NCATS

Clinical trial activity

1 trials · 2 clinical orgs · 1 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Jan 1, 2015 (NCT02323217)

Timeline

1950s

  1. Jul 1, 1959

    Validus Pharmaceuticals — Earliest FDA Approval

  2. Jul 1, 1959

    Validus Pharmaceuticals — NDA Secondary Org

  3. Jul 1, 1959

    Validus Pharmaceuticals — NDA Organization

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedJul 1, 1959

Chemistry & pharmacology

Loading structure…

SMILES

CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2
Mol. weight
231.2505 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warning

Sources

Also known as

  • benazide
  • isocarboxazid
  • isocarboxazid
  • isocarboxazid
  • isocarboxazid
  • isocarboxazid
  • isocarboxazid
  • isocarboxazid
  • isocarboxazid
  • isocarboxazid
  • isocarboxazid
  • isocarboxazid
  • isocarboxazida
  • isocarboxazida
  • isocarboxazide
  • isocarboxazide
  • isocarboxazide
  • isocarboxazidum
  • isocarboxazidum
  • isocarboxyzid
  • marplan
  • marplan
  • marplan
  • marplan
  • marplan
  • marplan
  • marplan
  • ro 5-0831
  • ro 5-0831/1

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02323217Early Phase 1 (Phase 1)Jan 1, 2015GlaxoSmithKline, University of London
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit1012015
University of LondonAcademic/Hospital1112015
2 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
Validus PharmaceuticalsFor profitNDA2Jul 1, 1959
Validus PharmaceuticalsFor profitNDAJul 1, 1959